Keywords: Amgen, BIND Biosciences, Licensing, Nanomedicines, GlaxoSmithKline, Priaxon, PriaXplore platform, Protein-protein interactions

Amgen in $180 mill deal with BIND; Priaxon accord with GlaxoSmithKline

Article | 09 January 2013

Print This

BIND Biosciences, a US clinical stage investor backed company, and Amgen (Nasdaq: AMNG), the world’s largest biotech firm, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in